Lupin announced that it has launched its Difizma indacaterol / glycopyrronium / mometasone DPI in India for the treatment of inadequately controlled asthma. The company says that Difizma is the first fixed dose combination approved for the treatment of poorly controlled asthma by the Drug Controller General of India (DCGI).
In 2022, Glenmark launched an indacaterol / mometasone DPI in India. Novartis’s Enerzair Breezhaler indacaterol / glycopyrronium / mometasone DPI has been approved in Europe and in Japan since 2020 and in Canada since 2021.
Lupin President, India Region Formulations, Rajeev Sibal commented, “We are excited about the launch of Difizma, a first-of-its-kind novel combination product available in India. Difizma is aimed at catering to the unmet need of patients with inadequately controlled asthma and aligns closely with Lupin’s ideology of patient-centricity and enabling accessibility for medicines.”
Read the Lupin press release.
